Spironolactone and potassium canrenoate in normal man.
The pharmacological activity of single doses of the two aldosterone antagonists, potassium canrenoate and spironolactone, was examined in two studies in healthy volunteers. Both drugs were active in reversing urinary electrolyte changes induced by fludrocortisone in periods 2 to 16 hr after treatment. Potassium canrenoate was significantly less potent that spironolactone on a weight or molar basis, with best estimates of the relative potency potassium canrenoate: spironolactone of approximately 0.3:1. On a weight basis the two drugs yielded plasma levels of the metabolite canrenone which were approximately equivalent. The results indicate that canrenone is not the principal pharmacologically active metabolite of spironolactone. Our study suggests that a major part of the renal antimineralocorticoid activity of spironolactone may be attributable to minor sulfur-containing metabolites or their precursors having a high renal clearance that affords access to their site of activity via the renal tubular fluid.
D002191:Canrenoic Acid / Q000494:pharmacology*; D002192:Canrenone / Q000097:blood / Q000652:urine; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011188:Potassium / Q000097:blood / Q000652:urine; D011245:Pregnadienes / Q000494:pharmacology*; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000494:pharmacology*; D013997:Time Factors
D011245:Pregnadienes; D013148:Spironolactone; D002192:Canrenone; D002191:Canrenoic Acid; D012964:Sodium; D011188:Potassium